Select your country

23.03.2018
STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

Read more

19.12.2017
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and Nidda Healthcare GmbH

STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and Nidda Healthcare GmbH

STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and …

Read more

27.09.2017
Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman

Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman

Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman

Read more

25.08.2017
Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Read more

10.07.2017
Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent

Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent

Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover of…

Read more

04.07.2017
Changes in the Executive Board of STADA Arzneimittel AG

Changes in the Executive Board of STADA Arzneimittel AG

Changes in the Executive Board of STADA Arzneimittel AG

Read more

04.07.2017
STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer

STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer

STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the…

Read more

26.06.2017
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

Read more

07.06.2017
STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5 percent – acceptance period extended until June 22, 2017

STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5 percent – acceptance period extended until June 22, 2017

STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5…

Read more

10.04.2017
STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share

STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share

STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share

Read more

17.03.2017
STADA raises medium-term growth targets

STADA raises medium-term growth targets

STADA raises medium-term growth targets

Read more

23.02.2017
STADA Arzneimittel AG informs about receipt of binding, conditional take-over offer

STADA Arzneimittel AG informs about receipt of binding, conditional take-over offer

Read more

16.02.2017
STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid

STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid

STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid

Read more

13.02.2017
STADA Arzneimittel AG starts talks with potential bidders

STADA Arzneimittel AG starts talks with potential bidders

STADA Arzneimittel AG starts talks with potential bidders

Read more

12.02.2017
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

Read more

27.08.2016
STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board

STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board

STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board

Read more

26.08.2016
STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

Read more

29.02.2016
STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

Read more

18.12.2015
STADA: Legal action against STADA’s Serbian subsidiary has been resolved

STADA: Legal action against STADA’s Serbian subsidiary has been resolved

STADA: Legal action against STADA’s Serbian subsidiary has been resolved

Read more

01.04.2015
STADA: Successful refinancing at favorable conditions through the placement of a further corporate bond in the total amount of Euro 300 million

STADA: Successful refinancing at favorable conditions through the placement of a further corporate bond in the total amount of Euro 300 million

STADA: Successful refinancing at favorable conditions through the placement of a further corporate bond in the total amount of Euro 300 mill…

Read more

24.03.2014
STADA: Successful financial year 2013 – Adjusted EBITDA reaches new record high – Dividend to increase by 32 percent – 2014 outlook adjusted

STADA: Successful financial year 2013 – Adjusted EBITDA reaches new record high – Dividend to increase by 32 percent – 2014 outlook adjusted

STADA: Successful financial year 2013 – Adjusted EBITDA reaches new record high – Dividend to increase by 32 percent – 2014 outlook adjusted…

Read more

14.02.2014
STADA: Local insolvency administrator files lawsuit against a subsidiary of STADA Arzneimittel AG

STADA: Local insolvency administrator files lawsuit against a subsidiary of STADA Arzneimittel AG

STADA: Local insolvency administrator files lawsuit against a subsidiary of STADA Arzneimittel AG

Read more

18.10.2013
STADA strengthens business activities in Russia with the signing of a contract for the purchase of the branded product portfolio Aqualor® for the self-medication of sinusitis and sore throat

STADA strengthens business activities in Russia with the signing of a contract for the purchase of the branded product portfolio Aqualor® for the self-medication of sinusitis and sore throat

STADA strengthens business activities in Russia with the signing of a contract for the purchase of the branded product portfolio Aqualor® fo…

Read more

16.08.2013
STADA purchases British OTC manufacturer Thornton & Ross

STADA purchases British OTC manufacturer Thornton & Ross

STADA purchases British OTC manufacturer Thornton & Ross

Read more

07.08.2013
STADA: Dr. Axel Müller resigns his Executive Board mandate

STADA: Dr. Axel Müller resigns his Executive Board mandate

STADA: Dr. Axel Müller resigns his Executive Board mandate

Read more

06.08.2013
STADA in exclusive negotiations on the purchase of the British OTC manufacturer Thornton & Ross

STADA in exclusive negotiations on the purchase of the British OTC manufacturer Thornton & Ross

STADA in exclusive negotiations on the purchase of the British OTC manufacturer Thornton & Ross

Read more